OncoMatch/Clinical Trials/NCT06704269
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Is NCT06704269 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for generalized myasthenia gravis.
This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage MGFA CLASS III, MGFA CLASS IVA (MGFA)
Excluded: Stage MGFA I, MGFA II, MGFA IVB, MGFA V
MGFA Class III-IVa (gMG) at screening; Exclusively ocular myasthenia gravis (MGFA I), mild symptoms (MGFA II), or severe bulbar disease or MG crisis, MGFA Class IVb or V at screening
Prior therapy
Must have received: non-steroidal immunosuppressive drug
adequate treatment trials with at least two different non-steroidal immunosuppressive drugs given at adequate doses and duration of therapy
Cannot have received: anti-CD19 therapy
Prior treatment with anti-CD19 therapy
Cannot have received: adoptive T cell therapy
Prior treatment with ... adoptive T cell therapy
Cannot have received: gene therapy product (CAR-T cell therapy)
Prior treatment with ... any prior gene therapy product (e.g. CAR-T cell therapy)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Univ Cali Irvine ALS Neuromuscular · Orange, California
- Wake Forest Univ School of Medicine · Winston-Salem, North Carolina
- Houston Methodist Hospital · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify